FAT-7 Xenograft Rat Model Service for Head and Neck Cancer

The FAT-7 xenograft rat model is a syngeneic, formaldehyde-induced nasal squamous cell carcinoma platform that preserves full host immunity while delivering rapid, reproducible tumor growth ideal for preclinical head and neck cancer drug development. Alfa Cytology leverages authenticated ATCC CRL-2109 cell stocks and standardized Fischer 344 implantation protocols to construct robust preclinical cohorts, supporting cytotoxic screening, immune-oncology evaluation, and novel therapeutic modality testing with rigorous histopathological and biomarker endpoints.

Overview of FAT-7 Xenograft Rat Model for Head and Neck Cancer

The FAT-7 cell line (ATCC CRL-2109) was established from a nasal squamous cell carcinoma induced by chronic formaldehyde inhalation in an adult male Fischer 344 rat, a model system originally developed to investigate occupational respiratory carcinogenesis. The line exhibits a point mutation in Tp53 (p.Arg271His, c.812G>A), a genetic alteration frequently observed in human head and neck squamous cell carcinoma (HNSCC) that disrupts DNA-damage response and apoptotic signaling. Histologically, FAT-7 produces poorly differentiated squamous cell carcinomas with prominent keratinization, intercellular bridges, and high mitotic activity, closely recapitulating the aggressive morphology of advanced human HNSCC. With an in vitro doubling time of approximately 24 hours, the line exhibits robust proliferative capacity that translates into rapid tumor establishment following implantation.

Fig 1. The establishment process of the rat orthotopic xenograft model. (Sever, ReidAnn E., et al., 2023)

As a syngeneic model, FAT-7 can be engrafted into immunocompetent Fischer 344 recipients, preserving intact tumor–immune crosstalk, antigen presentation, and stromal inflammatory responses that are ablated in immunodeficient human xenograft systems. This feature makes the model particularly valuable for evaluating immune-modulatory agents, oncolytic viruses, and combination regimens that depend on functional T-cell, macrophage, and natural killer cell populations. Tumors can be established via subcutaneous flank injection for straightforward tumor growth monitoring or orthotopically into the floor of the mouth or tongue to model anatomically relevant HNSCC progression, including local invasion and regional lymph node metastasis. The high tumor take rate and reproducible growth kinetics have cemented FAT-7 as a cornerstone preclinical tool for head and neck cancer therapeutic development.

Cell Line Information: FAT-7

The table below summarizes the authenticated characteristics of the FAT-7 rat nasal squamous cell carcinoma cell line, compiled from ATCC repository data, Cellosaurus records, and peer-reviewed literature.

Our Services

Alfa Cytology operationalizes the FAT-7 platform through a fully documented preclinical pipeline: authenticated master and working cell banks maintained under low-passage conditions, surgical implantation by experienced veterinary surgeons in either subcutaneous or orthotopic configurations, longitudinal tumor monitoring via caliper and imaging modalities, and terminal histopathology with quantitative biomarker readouts. Every study is designed to align with your compound's mechanism of action—whether small-molecule cytotoxics, biologics, oncolytic viruses, or immune-modulatory agents—with all work conducted under accredited IACUC oversight and GLP-aligned documentation standards.

Workflow of FAT-7 Xenograft Rat Model Construction

Construction of the FAT-7 syngeneic head and neck cancer model follows a reproducible surgical and cell-biology workflow optimized for high tumor take rates, consistent growth kinetics, and minimal perioperative morbidity. The protocol can be adapted for subcutaneous flank implantation or orthotopic tongue/floor-of-mouth injection depending on the scientific objective.

1. Cell Line Resuscitation & Quality Control: Cryopreserved FAT-7 stocks (ATCC CRL-2109) are thawed and expanded in antibiotic-free complete medium under low-passage conditions. Cell identity is confirmed by morphology and STR profiling against the authenticated reference (RRID: CVCL_3511). Harvest occurs at 70–80% confluence using 0.05% trypsin-EDTA; viability is assessed by trypan blue exclusion, with only suspensions exceeding 95% viability advanced to implantation. Cells are washed in PBS and resuspended in serum-free medium at a concentration of 1–2 × 10⁶ cells per 100 µL for subcutaneous injection, or at 5 × 10⁵ cells per 50 µL for orthotopic delivery.
2. Recipient Preparation & Anesthesia: Adult Fischer 344 rats (typically 8–12 weeks old, 180–220 g) are acclimated for one week prior to surgery. On the day of implantation, animals are anesthetized with isoflurane inhalation (2–3% in oxygen) or ketamine/xylazine cocktail, with continuous monitoring of respiratory rate, heart rate, and pedal reflex. Ophthalmic ointment is applied to prevent corneal desiccation, and the surgical field is shaved and disinfected with alternating betadine and ethanol scrubs.
3. Tumor Cell Implantation: For subcutaneous models, 100 µL of the FAT-7 single-cell suspension is injected into the right flank using a 25-gauge needle. For orthotopic models, a small incision is made in the floor of the mouth or lateral tongue; the FAT-7 cell suspension is delivered into the submucosal layer using a 30-gauge Hamilton syringe. The injection site is sealed with surgical adhesive or a small suture, and the incision is closed with absorbable suture. Analgesia (buprenorphine, 0.05–0.1 mg/kg) is administered subcutaneously immediately post-surgery.
4. Post-Operative Monitoring & Tumor Tracking: Animals are housed individually or in small groups on warming pads until fully conscious. Body weight, food intake, and incision integrity are monitored daily for the first 72 hours, then twice weekly. Subcutaneous tumors are measured with digital calipers (volume = L × W² / 2) from the first palpable detection, typically 7–10 days post-implantation. Orthotopic tumors are monitored by longitudinal ultrasound or MRI starting at day 10. Clinical signs including dysphagia, weight loss, and regional lymph node enlargement are recorded.
5. Therapeutic Intervention & Endpoint Harvest: Upon reaching the target tumor volume (typically 100–200 mm³ for subcutaneous; 50–100 mm³ for orthotopic by imaging), animals are randomized into treatment and control cohorts. Test articles are administered according to the sponsor-defined regimen—intravenous, intraperitoneal, oral gavage, intratumoral, or peritumoral. Tumor measurements continue on schedule until the study endpoint, at which time animals are humanely euthanized. Tumors, draining cervical lymph nodes, lungs, liver, and blood are harvested. Tumor weight is recorded, tissues are digitally imaged, and samples are snap-frozen, fixed in formalin, or submerged in RNAlater for downstream H&E histopathology, Ki-67 proliferation index, TUNEL apoptosis scoring, CD3/CD68 immune infiltration analysis, and plasma pharmacokinetic profiling.

Fig 2. FAT-7 Xenograft Rat Model construction workflow.

Case Study-FAT-7 Xenograft Rat Model Development

In a recent preclinical program, Alfa Cytology utilized the FAT-7 subcutaneous syngeneic model to evaluate the antitumor activity of a novel oncolytic virus candidate engineered to selectively replicate in p53-deficient squamous cell carcinoma cells. Following authenticated FAT-7 cell expansion and implantation into Fischer 344 rats, tumors were permitted to establish for 10 days prior to randomization into vehicle, low-dose, and high-dose cohorts. The oncolytic virus was administered via intratumoral injection on days 10, 14, and 18, with longitudinal tumor volume monitoring and interim body-weight assessments. Terminal analyses included H&E histopathology to assess necrotic fraction, CD3 and CD68 immunohistochemistry to quantify T-cell and macrophage infiltration, and quantitative PCR to measure viral genome copy number in tumor tissue. The dataset revealed dose-dependent tumor growth delay accompanied by marked immune cell recruitment and viral replication persistence, furnishing the sponsor with pharmacodynamic evidence to support downstream vector optimization and IND-enabling toxicology planning.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your FAT-7 head and neck cancer program means accessing a specialized preclinical infrastructure built around reproducible syngeneic modeling, multimodal analytics, and regulatory-grade documentation.

• Authenticated FAT-7 master and working cell banks are maintained under documented low-passage protocols with periodic STR verification to ensure genetic stability and consistent tumorigenicity in Fischer 344 recipients.
• Our surgical team has extensive experience in rat subcutaneous and orthotopic head and neck implantation, achieving high tumor take rates with minimal perioperative mortality through refined anesthesia and post-operative pain management.
• The syngeneic nature of the FAT-7 model preserves intact immune surveillance, enabling robust evaluation of immune-oncology agents, oncolytic viruses, and combination regimens that require functional T-cell and macrophage responses.
• Integrated endpoint packages span standard caliper-based tumor tracking through to advanced histopathology, multiplex cytokine profiling, flow cytometric immune phenotyping, and plasma drug-concentration analysis.
• Study protocols are customized to your therapeutic modality, whether the focus is cytotoxic chemotherapy, targeted biologics, oncolytic virotherapy, or immune checkpoint inhibitors, with clear go/no-go decision criteria.
• All in vivo work is conducted under fully accredited IACUC oversight with real-time veterinary monitoring and GLP-aligned documentation, ensuring ethical integrity and generating audit-ready data packages for regulatory submissions.

Contact Us

If your head and neck cancer therapeutic pipeline requires a preclinical model that couples p53-mutant squamous cell carcinoma biology with intact immune surveillance and translational relevance, reach out to us to discuss how Alfa Cytology can architect a FAT-7 study tailored to your development milestones. Our scientific team will review your target profile, propose a customized protocol with integrated pharmacodynamic and immune-monitoring endpoints, and deliver a comprehensive proposal within 48 hours. Contact us today and accelerate your preclinical proof-of-concept with a CRO that understands the nuances of syngeneic head and neck cancer modeling.

For research use only. Not intended for any clinical use.